156 related articles for article (PubMed ID: 36755439)
21. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
[TBL] [Abstract][Full Text] [Related]
22. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
23. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
[TBL] [Abstract][Full Text] [Related]
24. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
26. Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank.
Li B; Sangkuhl K; Whaley R; Woon M; Keat K; Whirl-Carrillo M; Ritchie MD; Klein TE
Am J Hum Genet; 2023 Oct; 110(10):1628-1647. PubMed ID: 37757824
[TBL] [Abstract][Full Text] [Related]
27. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing?
Lopes JL; Harris K; Karow MB; Peterson SE; Kluge ML; Kotzer KE; Lopes GS; Larson NB; Bielinski SJ; Scherer SE; Wang L; Weinshilboum RM; Black JL; Moyer AM
J Mol Diagn; 2022 Mar; 24(3):253-261. PubMed ID: 35041929
[TBL] [Abstract][Full Text] [Related]
28. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
29. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Chang WC; Hung SI; Carleton BC; Chung WH
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.
Alshabeeb MA; Alyabsi M; Paras B
Saudi Pharm J; 2022 Aug; 30(8):1181-1192. PubMed ID: 36164570
[TBL] [Abstract][Full Text] [Related]
31. Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia.
Kothary AS; Mahendra C; Tan M; Min Tan EJ; Hong Yi JP; Gabriella ; Hui Jocelyn TX; Haruman JS; Tan Z; Lee CK; Lezhava A; Yan B; Irwanto A
Pharmacogenomics; 2021 Nov; 22(16):1041-1056. PubMed ID: 34693729
[No Abstract] [Full Text] [Related]
32. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.
Sorich MJ; Rowland A; McKinnon RA; Wiese MD
Circ Cardiovasc Genet; 2014 Dec; 7(6):895-902. PubMed ID: 25258374
[TBL] [Abstract][Full Text] [Related]
33. CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
Tan DS; Aw JWX; Winther M; Goh LL; Ong HY; Wee E; Liu J; Ho HK
J Clin Pharm Ther; 2020 Feb; 45(1):52-58. PubMed ID: 31670842
[TBL] [Abstract][Full Text] [Related]
34. Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States.
Stevenson JM; Alexander GC; Palamuttam N; Mehta HB
Clin Transl Sci; 2021 Jan; 14(1):153-162. PubMed ID: 33085221
[TBL] [Abstract][Full Text] [Related]
35. Effects of the
Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
[TBL] [Abstract][Full Text] [Related]
36. Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice.
Russmann S; Rahmany A; Niedrig D; Hatz KD; Ludin K; Burden AM; Englberger L; Backhaus R; Serra A; Béchir M
Eur J Clin Pharmacol; 2021 May; 77(5):709-716. PubMed ID: 33242107
[TBL] [Abstract][Full Text] [Related]
37. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.
Dorji PW; Tshering G; Na-Bangchang K
J Clin Pharm Ther; 2019 Aug; 44(4):508-524. PubMed ID: 30980418
[TBL] [Abstract][Full Text] [Related]
38. Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
Biswas M; Kali SK
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1147-1159. PubMed ID: 33523336
[TBL] [Abstract][Full Text] [Related]
39. Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
Fohner AE; Rettie AE; Thai KK; Ranatunga DK; Lawson BL; Liu VX; Schaefer CA
Clin Transl Sci; 2020 Sep; 13(5):1004-1009. PubMed ID: 32216088
[TBL] [Abstract][Full Text] [Related]
40. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
